No study has examined the GLOW combination
No in vitro, animal or human study of GHK-Cu + BPC-157 + TB-500 together.
PrecisePep/Blends & Stacks/GLOW
Regenerative Blend
GLOW
GHK-Cu + BPC-157 + TB-500 · KLOW without KPV
The three-component predecessor to KLOW — structural repair plus matrix remodelling, weighted toward skin and connective tissue, with no immune-modulating component.
00 Overview
GLOW came first. Three peptides covering structural repair — matrix remodelling from GHK-Cu, local angiogenesis from BPC-157, systemic cell mobilisation from TB-500. It is the blend most associated with skin quality, scar appearance and connective tissue, and it remains widely used in its own right rather than only as a KLOW precursor.
The argument for adding KPV — and thereby producing KLOW — is that GLOW has no immune-modulating component, and chronic inflammatory signalling obstructs the resolution phase of healing. That argument is persuasive where the underlying problem is inflammatory. Where the objective is dermal quality or matrix remodelling, the fourth component adds an immunosuppressive mechanism that is not obviously needed.
The evidence situation is identical to KLOW's: no study has ever examined the combination. GHK-Cu has the best human data of the three, and it is topical — a route that delivers no systemic copper at all, which is worth sitting with before injecting a copper-containing blend for a skin outcome.
GLOW or KLOW?
The distinction is one component. If the target is inflammatory — gut, autoimmune-adjacent, chronic inflammatory injury — the KPV arm in KLOW is the reason to choose it. If the target is dermal or structural, GLOW covers it with one fewer mechanism and one fewer unknown. If the target is tendon or ligament specifically, the Wolverine stack covers it with no copper at all.
// Mechanism of action
GHK-Cu — matrix. Stimulates collagen, elastin, decorin and glycosaminoglycan synthesis while simultaneously upregulating matrix metalloproteinases and their inhibitors, driving turnover rather than simple deposition. Copper delivery supports lysyl oxidase, the enzyme that cross-links collagen and elastin. This is what gives GLOW its dermal weighting.
BPC-157 — perfusion. VEGFR2 upregulation and nitric oxide signalling drive local angiogenesis, delivering substrate to the tissue being remodelled.
TB-500 — mobilisation. Actin regulation enabling repair-cell migration, plus anti-fibrotic signalling that shapes the quality of the resulting tissue.
Practical interaction. BPC-157 is widely reported to reduce the injection-site sting of GHK-Cu. Observation rather than characterised pharmacology, but consistent.
What is absent. No component of GLOW suppresses NF-κB. In a chronic inflammatory state, the matrix and repair signalling is working against a persistent inflammatory background — the entire rationale for KLOW.
// What is in it
A blend is not a compound. It is several compounds sharing a vial, and each one carries its own evidence base, dose-response curve and risk profile. Study them individually before studying them together.
| Component | Share of blend | Role in the blend | Monograph link |
|---|---|---|---|
| GHK-Cu Copper tripeptide |
~50 mg of 70 (71%) | Matrix remodelling and dermal regeneration — collagen, elastin and glycosaminoglycan synthesis with MMP-driven clearance of damaged matrix. The reason GLOW is the skin-weighted blend. | Monograph |
| BPC-157 Pentadecapeptide |
~10 mg of 70 (14%) | Local repair — angiogenesis, nitric oxide signalling, fibroblast recruitment, gut barrier. | Monograph |
| TB-500 Thymosin β4 fragment |
~10 mg of 70 (14%) | Systemic cell mobilisation and anti-fibrotic remodelling. | Monograph |
Blend arithmetic
The common presentation is a 70 mg vial — exactly the 80 mg KLOW vial minus its 10 mg of KPV, which points to the same 50 mg GHK-Cu plus 10 mg BPC-157 plus 10 mg TB-500 split. Suppliers do not publish this, so treat it as a working assumption rather than a specification.
If it holds, GLOW is around 71% copper peptide by mass — a higher copper fraction than KLOW, because removing KPV removes non-copper mass. That is consistent with GLOW being the skin-weighted blend, and it means the copper-load and zinc-balance questions apply here at least as strongly.
Ask your supplier for the split. If it is not provided, the weekly copper delivery cannot be calculated — use the blend calculator to rescale once you have it.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Component evidence: GHK-Cu human topical skin data [1]
Controlled dermatological studies reporting increased collagen, improved elasticity and reduced wrinkle depth and photodamage. The strongest human evidence of any component in this blend — by the topical route.
Component evidence: GHK-Cu wound healing and matrix turnover [1][2]
Accelerated wound closure and MMP-2 upregulation in fibroblast culture, supporting the remodelling model of action.
Component evidence: BPC-157 rodent repair literature [3]
Tendon, ligament, gut and vascular healing models, predominantly from one research programme.
Component evidence: thymosin β4 repair and anti-fibrotic activity [4]
Animal and human topical evidence for the parent protein.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Improved skin quality, elasticity and firmness
The primary use case, resting on the strongest component evidence — though that evidence is topical. Whether subcutaneous injection reproduces a dermal effect established for topical application is an open question the blend market does not address.
Reduced skin laxity after significant weight loss
The most common reason GLOW appears in a metabolic stack.
Improved scar appearance
Combines GHK-Cu remodelling with TB-500 anti-fibrotic signalling. Plausible for developing scar; established mature scar is a harder target.
Connective tissue and tendon support
Covered by BPC-157 and TB-500 — which means the Wolverine stack covers it too, without copper.
Hair and follicle effects
From the GHK-Cu follicle literature. Topical scalp application is the evidenced route, not systemic injection.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Visible skin improvement in 4–8 weeks
The dominant community report for this blend, and the one best aligned with component evidence.
Reduced skin laxity during a cut
Widely reported; impossible to separate from the natural retraction that occurs over the same timescale.
Joint and tendon relief
Reported, and attributable to the BPC-157/TB-500 fraction rather than anything GLOW adds over Wolverine.
Injection-site sting
Better than standalone GHK-Cu, worse than Wolverine. The defining practical complaint.
Fatigue on long continuous runs
The copper-related signal driving cycling.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination safety data
None exists for the three-peptide combination.
Copper toxicity and zinc antagonism [5]
The characterised risk. Copper excess causes hepatic and neurological injury; copper loading depresses zinc. Injected copper bypasses intestinal absorption control.
Two pro-angiogenic components [4]
BPC-157 and TB-500 both promote angiogenesis and cell migration; thymosin β4 expression is associated with tumour progression in oncology literature.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Cumulative copper load at unknown ratio
Identical to KLOW: daily dosing over months at an undisclosed GHK-Cu fraction means unknown weekly copper delivery.
Zinc depletion and over-correction
Both directions of the copper–zinc ratio cause harm, and neither is guessable without labs.
Inability to isolate an adverse effect
Three candidate causes stop together.
Route mismatch for the primary use case
The skin evidence is topical. Injecting for a dermal outcome delivers systemic copper for a benefit that has only been demonstrated locally.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Injection-site stinging and redness
The most reported effect.
Metallic taste, headaches, fatigue
Copper-consistent signals on prolonged use.
Blue-tinted solution and occasional site discolouration
Expected — the blue is the copper complex.
Vendor-to-vendor inconsistency
Different sting, colour and effect between nominally identical blends.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No studied dose exists
Component doses are not additive and were established by different routes in different models.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Dose by copper content
Elemental copper per week is the exposure that matters. A blend milligram figure does not convey it.
Cycle on the copper, not the blend
Rotating to Wolverine keeps the two non-copper components continuous.
Consider topical GHK-Cu instead for skin goals
It is the evidenced route and delivers no systemic copper.
Dilute generously to reduce sting
Lower local copper concentration at the injection site.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
1.5–3 mg total blend daily
The general community range, ratio-dependent.
4–8 weeks on, 4 weeks off
Standard cycling, driven by the copper component.
Rotated with Wolverine
The same structure used for KLOW.
Zinc alongside, guided by labs
The mitigation practice, with bloodwork as the sensible prerequisite.
| Phase | Blend | Daily dose | Duration |
|---|---|---|---|
| Repair phase | GLOW | 1.5 – 3 mg | 4–8 weeks |
| Copper break | Wolverine or nothing | 1 mg / — | 4 weeks |
| Skin-focused alternative | Topical GHK-Cu | 1–3 mg/mL | Continuous |
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination studies exist
The blend has never been studied as a blend.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Internal synergy — matrix, perfusion, mobilisation
Three phases of repair covered. Coherent, untested.
Adding KPV produces KLOW
The upgrade path, justified where inflammatory signalling is the limiting factor.
Removing GHK-Cu produces Wolverine
The downgrade path, justified where the target is tendon rather than skin and copper exposure is unwanted.
GLOW alongside aggressive fat loss
The skin-elasticity rationale. The most common stack context.
Antagonism to manage: zinc
Used against the copper component, not with the blend.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Used interchangeably with KLOW
Community practice frequently treats the two as substitutes, which understates the difference the KPV arm makes for inflammatory targets.
Paired with topical GHK-Cu
Reported for skin-focused goals. Doubles total copper exposure.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No protocol has been studied
No trial or registered protocol exists for the blend.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
What actually sets the duration — and what does not
Worth separating the two components that drive this decision, because they point opposite ways. The peptide repair components are the argument for running long. BPC-157’s rodent literature is not confined to the injection site — intragastric and intraperitoneal dosing produce distant-organ effects, so it behaves systemically rather than as a local agent. And Tβ4 has the one published head-to-head on schedule: in rat chronic myocardial ischaemia, long-term dosing reduced infarct size and improved function where short-term dosing only trended that way. Human phase 1 work found no accumulation across repeated doses. What limits the course is the copper. GHK-Cu is the component with a cumulative-exposure rationale, and the rotation exists to let copper homeostasis normalise — not because BPC-157 or TB-500 have been shown to lose effect. No tachyphylaxis study exists for either peptide, so “no tolerance” remains an absence of evidence rather than a finding.
Copper-status-guided cycling
Serum copper, ceruloplasmin and zinc should set the off-period rather than a vial count.
Choose the blend that matches the target
Wolverine for tendon, GLOW for skin and matrix, KLOW where inflammation is the limiting factor. Escalating to the largest blend by default maximises exposure without matching mechanism to problem.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
4–8 weeks on, 4 weeks off
The general community structure.
15-Compound Matrix — Q2 regenerative pillar
Grouped with KLOW and Wolverine in the regenerative and tissue repair category.
05b Condition-specific interest
GLOW is a cosmetic-facing blend and the honest reading of it is that one of its three components has real human evidence for skin — by a route this blend does not use. That single fact organises everything below.
No approval, no trial
No component of this blend is approved, and the blend has never been studied as a blend. The GHK-Cu evidence people cite for skin is topical, at cosmetic concentrations, applied to the skin being treated. This is an injectable vial containing that compound at a dose orders of magnitude larger, delivered systemically. Those are not the same intervention, and the ratio here is inferred rather than supplier-stated — check what you have.
Study for the component, topically — not for this product
Skin quality, ageing and photodamage
Pathophysiology
Photoaged skin shows fragmented collagen, reduced dermal thickness and a shift toward matrix degradation over synthesis.
Mechanistic rationale
Copper is a required cofactor for lysyl oxidase, which cross-links collagen and elastin, and controlled human topical studies of GHK-Cu have reported improvements in skin density, wrinkle depth and elasticity. That evidence used a serum on skin. The argument for injecting it is that systemic delivery reaches the dermis from below — which is plausible, unstudied, and delivers a copper load the topical route never approaches. See the copper entry.
Community reports
The most common reason people buy this blend. Skin appearance is highly responsive to sleep, hydration, sun exposure and expectation, and it is assessed by looking in a mirror, which makes it among the least reliable endpoints in this library.
Components carrying the argument: GHK-Cu — carrying essentially the whole argument
Theorized — with the component evidence being older
Wound healing, scarring and post-procedure recovery
Pathophysiology
Wound closure depends on cell migration into the defect and on the blood supply to sustain it. Excess or disorganised matrix deposition in the same process produces hypertrophic scar.
Mechanistic rationale
All three components have a stake here: GHK-Cu on matrix synthesis and remodelling, TB-500 on cell migration and reported anti-fibrotic effects, BPC-157 on angiogenesis. It is the most internally coherent argument for the blend — three agents on three genuinely different steps of one process, rather than three agents on the same step.
Community reports
Used after microneedling, laser and minor surgery. Post-procedure erythema and healing resolve on their own over a predictable timescale, which is the comparator nobody applies.
Components carrying the argument: GHK-Cu matrix + TB-500 migration + BPC-157 angiogenesis
Theorized — you may be buying the wrong blend
Tendon and soft-tissue injury
Pathophysiology
Tendon repair is limited by vascularity and by cell migration into a poorly perfused injury.
Mechanistic rationale
The BPC-157 and TB-500 components are the same two compounds that make up Wolverine, which exists specifically for this purpose — and typically at a higher dose of each, since GLOW allocates most of its mass to GHK-Cu. If soft-tissue injury is the goal, GLOW is a more expensive way to get less of the two components that address it.
Community reports
People frequently choose GLOW for injury on the assumption that a third component must help. Check the vial composition against what you are actually trying to do.
Components carrying the argument: BPC-157 + TB-500, at a lower share of the vial
Actionable warning
Copper load — the item that matters most
Pathophysiology
Copper is essential in a narrow range and has no rapid excretion route — elimination is biliary and slow. Chronic excess causes hepatic and neurological injury, which is the mechanism of Wilson disease.
Mechanistic rationale
GHK-Cu is a copper delivery vehicle, and it is the largest component of this blend by mass — typically around 50 mg of a 70 mg vial. A cosmetic serum delivers a trivial amount to skin. Daily systemic injection at this scale is a different exposure entirely, with no monitoring attached. Copper and zinc also compete for absorption and transport, so sustained copper loading can produce functional zinc deficiency.
Community reports
Serum copper and ceruloplasmin are cheap, ordinary blood tests, and community discussion of them is close to absent. Metallic taste, nausea and abdominal discomfort at higher doses are consistent with copper excess and are usually attributed to the injection.
Components carrying the argument: The copper in GHK-Cu, at blend-scale doses
Theorized — unresolved
The oncology caution applies to all three components
Pathophysiology
Angiogenesis and matrix remodelling are hallmarks of tumour growth and invasion, and are also exactly what tissue repair requires.
Mechanistic rationale
Every component of this blend is pro-angiogenic or matrix-active, so the standing caution in this library applies here with the least dilution of anywhere. No human study has shown any of them causes or accelerates cancer, because none has looked. Anyone with a current or past malignancy should be having this conversation with an oncologist.
Community reports
Rarely raised before use, which is the point of stating it here.
Components carrying the argument: All three
| Use | Which component | Evidence | The thing to know |
|---|---|---|---|
| Skin ageing | GHK-Cu | Human RCT — topical | The trials used a serum, not a syringe |
| Wound / post-procedure | All three | Animal + older human | Most coherent argument for the blend |
| Tendon / soft tissue | BPC-157 + TB-500 | Rodent | Wolverine gives more of both, for less |
| Copper exposure | GHK-Cu | — | ~50 mg of a 70 mg vial, systemic, unmonitored |
| Cancer caution | All three | Unresolved | Angiogenesis is the shared property |
| Blend ratio | — | — | Inferred, not supplier-stated — verify yours |
What actually has evidence for these conditions
For skin ageing: sun protection is the highest-yield intervention available and nothing on this page competes with it. Topical retinoids have the strongest evidence of any topical agent for photoageing. Topical GHK-Cu has its own reasonable human evidence — applied to skin, which is how the trials were run and how it is sold as a cosmetic. Sleep, not smoking, and treating rosacea or dermatitis where present all move the same needle.
For wounds and scars: debridement, offloading, moisture balance and infection control for chronic wounds. For scar: silicone, pressure, sun protection and time — scars remodel for a year or more, so early assessment misleads.
For tendinopathy: progressive mechanical loading over months has the best evidence of any intervention, and beats every injectable it has been compared against.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied pre-blended, most commonly 70 mg total per vial. Reconstituted with bacteriostatic water; larger dilution volumes reduce injection-site sting, which matters given the high copper-peptide fraction. Solution should carry a strong blue tint.
Storage
Lyophilised: refrigerated or frozen, protected from light. Reconstituted: 2–8 °C.
Common vial sizes
Most commonly a 70 mg total vial - the same components as KLOW without the 10 mg of KPV.
Stability notes
Absence of blue tint suggests no GHK-Cu or a dissociated complex.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use in any jurisdiction. No component is approved for injection; GHK-Cu has cosmetic-ingredient status for topical use only. BPC-157 has been identified by the FDA as presenting significant safety risks for compounding use.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: component status: BPC-157 and TB-500 recommended July 2026; GHK-Cu pending Feb 2027. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
BPC-157 (S0) and thymosin β4 analogues (S2) are both explicitly prohibited by WADA. Any blend containing them is prohibited at all times.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.Review or meta-analysis
- Simeon A, et al. The tripeptide-copper complex GHK-Cu²⁺ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000.In vitro / cell study
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011.Review or meta-analysis
- PubMed: thymosin beta 4 — repair, anti-fibrotic activity and tumour association (live query)Database or literature search
- NIH Office of Dietary Supplements — Copper: fact sheet for health professionalsRegulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.